Structured Abstract
Please note: In 2003, the CTF updated its Grades of
Recommendations to include an "I Recommendation" for situations where
insufficient evidence exists to allow a recommendation to be made.
(Formerly, these situations were captured under a "C
Recommendation".) This change is not retroactive, and all
"C Recommendations" made prior to 2003 have not been
reevaluated in light of the new "I" recommendation grade. For a
discussion of these recommendation grades, please link to the 2003 article in
the Canadian Medical Association Journal here.
Prevention of Osteoporotic Fractures in Women by Estrogen Replacement Therapy
Prepared by Denice S. Feig, MD, FRCPC, Assistant Professor of Medicine,
University of Toronto
These recommendations were finalized by the Task Force in October 1993
Contents
Objective
To make recommendations for screening postmenopausal women in Canada to
identify those who are at risk for osteoporotic fractures and would benefit
from estrogen replacement therapy (ERT).
Burden
of Suffering
The most common age-related fractures are those of the distal forearm,
vertebrae, and hip. Vertebral fractures are the most common of the osteoporotic
fractures. The estimated lifetime risk for a 50 year old woman of sustaining
a vertebral fracture is 32%. Hip fractures are associated with more death,
morbidity and medical costs than all other osteoporotic fractures combined.
The incidence begins to rise after age 50 but rises dramatically after
age 70. Mortality rates in the first year following a hip fracture are
12-20% higher than rates in those of similar age and sex who have not sustained
a fracture. In the U.S. the cost of acute care attributable to osteoporosis
was estimated at U.S. $7-10 billion in 1984.
Options
Screening methods include history and physical examination, single and
dual photon absorptiometry, and measures of bone density (quantitative
computed tomography, neutron activation analysis, and dual x-ray absorptiometry).
The main treatment option was counselling women about the benefits and
risks of ERT. Treatment options for ERT include percutaneous estrogen,
oral estrogen alone, or oral estrogen combined with progesterone.
Outcomes
Accuracy of tests. ERT-related outcomes include bone mineral loss, fractures,
cardiovascular mortality and events, and breast and endometrial cancer.
Evidence
MEDLINE was searched starting in 1987 using the keywords "osteoporosis",
"estrogen replacement therapy", "synthetic estrogens", "evaluation studies",
"random allocation", "double-blind method", "drug evaluation", "random",
"cohort studies", "clinical trial", "menopause", "postmenopausal", and
"English". Reference material was consulted and content experts contacted.
Only studies of women were included. Study results were synthesized in
table or graphic format only.
Recommendations were graded as:
|
A
|
Good evidence to support the recommendation that the condition
be specifically considered in a PHE. |
|
B
|
Fair evidence to support the recommendation that the condition
be specifically considered in a PHE. |
|
C
|
Poor evidence regarding inclusion or exclusion of the condition
in a PHE, but recommendations may be made on other grounds. |
|
D
|
Fair evidence to support the recommendation that the condition
be specifically excluded from consideration in a PHE. |
|
E
|
Good evidence to support the recommendation that the condition
be specifically excluded from consideration in a PHE. |
Quality of evidence was rated according to 5 levels:
|
I
|
Evidence from at least 1 properly randomized controlled
trial (RCT). |
|
II-1
|
Evidence from well-designed controlled trials without randomization. |
|
II-2
|
Evidence from well-designed cohort or case-control analytic
studies, preferably from more than 1 centre or research group. |
|
II-3
|
Evidence from comparisons between times or places with
or without the intervention. Dramatic results in uncontrolled experiments
could also be included here. |
|
III
|
Opinions of respected authorities, based on clinical experience,
descriptive studies or reports of expert committees. |
Values
The 13-member Task Force of experts in family medicine, geriatric medicine,
pediatrics, psychiatry and epidemiology used an evidence-based method for
evaluating the effectiveness of preventive health care interventions. Recommendations
were not based on cost-effectiveness of options. Patient preferences were
not discussed.
Background papers providing critical appraisal of the evidence and tentative
recommendations prepared by the chapter author were pre-circulated to the
members. Evidence for this topic was presented and deliberated upon in
1- to 2-day meetings, 2 to 3 times per year from January 1993 to June 1993.
Consensus was reached on final recommendations.
Benefits,
Harms, and Costs
The benefits of estrogen replacement therapy must be weighed against its
risks. Simple and complex models and procedures for detecting women at
risk for fractures have not been successful. No randomized controlled trials
have been done to show that screening asymptomatic women can decrease the
rate of fractures.
There is good evidence, from RCTs, of that short-term percutaneous estrogen,
oral estrogen, or estrogen and progesterone therapy show prevention of or retard
bone loss or and even increases in bone mineral density but the studies
have not been linked with decreased risk or occurrences of fractures. Case-control
studies, cohort studies, and 1 RCT have shown that ERT prevents osteoporotic
fractures including hip fractures (point estimates of the relative risk
are from 0.65 to 0.79, P < 0.05).Optimal duration of ERT has
not been established. One meta-analysis showed that women who had ever
used estrogen had a decreased risk for both coronary heart disease (relative
risk [RR] 0.65, 95% CI 0.59 to 0.71) and cardiac death (RR 0.63, CI 0.55
to 0.72).
Risks of ERT include increased rates of endometrial and breast cancer.
For endometrial cancer, the addition of progesterone decreases the risk
of incurred by using estrogen alone: one study showed a decrease in risk
for endometrial cancer with an incidence in estrogen users of 359 per 100
000, in estrogen progesterone-users of 56 per 100 000, and in untreated
women of 248 per 100 000. One meta-analysis showed that long-term use (after
15 years) of estrogen had an RR for breast cancer of 1.3 (CI 1.2 to 1.6)
for all women after 15 years of estrogen use. For studies assessing family
history, the RR for breast cancer was 3.4 (CI 2.0 to 6.0) for women with
a family history of breast cancer and 1.5 (CI 1.2 to 1.7) for women without
a family history. Three other meta-analyses did not show an increased risk
for breast cancer after short-term estrogen use. No evidence exists for
combination therapy to reduce breast cancer risk.
Recommendations
Recommendation grade [A, B, C, D, E] and level of evidence
[I, II-1, II-2, II-3, III] are indicated after each recommendation. Citations
in support of individual recommendations are identified in the guideline
text.
-
There is poor evidence to include or exclude, in the PHE of asymptomatic
women, initial history taking and physical examination to detect risk factors
for osteoporotic fractures [C, II-2].
No evidence exists for using the physical examination and history taking
as screening tools for risk for fractures in postmenopausal women [C,
II-2].
-
Fair evidence exists to exclude, from the PHE of asymptomatic women, single
and dual photon absorptiometry, quantitative computed tomography, neutron
activation analysis, and dual x-ray absorptiometry in the periodic health
examination [D, II-2].
-
Fair evidence exists to include, in the PHE, counselling for all perimenopausal
women regarding the benefits and risks of ERT [B,
I, II-2].
Validation
This report was externally peer reviewed. This report was externally peer-reviewed.
The 1989 U.S. Preventive Services Task Force recommended against routine
screening for decreased bone mass in asymptomatic women; it could be considered
when
the information was to be used in decision-making for ERT. A Consensus
Development Conference of the European Foundation of Osteoporosis and Bone
Disease, the National Osteoporosis Foundation and the National Institute
of Arthritis and Musculoskeletal and Skin Disease of the United States
recommended that all women at risk for osteoporosis be considered for estrogen
therapy, barring contraindications. They also suggested that bone density
measurements could aid in predicting risk.
Sponsors
The Canadian Task Force on Preventive Health Care
developed this guideline with funding from Health Canada.
Selected
References
Source Document
Link to Full Text of this
review
Link to Summary Table of Recommendations of this review
Link to Selected References list of this review
Top of Page
CTFPHC
Home Page
Copyright © 1997 Canadian
Task Force on Preventive Health Care
For any technical issues please contact: webmaster@ctfphc.org
Last modified: June 10, 1998.